GET DAILY SIGNALSGreenwich LifeSciences (GLSI) Eases About -2% Over 30 Days While Holding Near Key Averages
Key Takeaways
- GLSI shares have traded roughly flat over the last 30 days, easing about 2% from the mid-$16 level despite intraday swings between roughly $14 and $19.
- The stock remains below its 200-day moving average near $19.89 but has held near its 50-day moving average around $16.63.
- Investor attention centers on the Phase III FLAMINGO-01 trial of GLSI-100, the company's lead immunotherapy designed to prevent breast cancer recurrence.
- Analyst sentiment is mixed: HC Wainwright maintains a Buy with a $69 price target, while the broader consensus averages to a Hold and a third-party ratings firm downgraded the stock in late October.
- Greenwich LifeSciences is expected to report Q3 2026 results around November 13, 2026, with a consensus loss of $0.34 per share.
- For additional detail, explore the company's Price Targets, Earnings, and Forecast pages.
- You can also discover automated trading strategies and signals by exploring Trending AI Robots.
Current Trading Snapshot for GLSI
Greenwich LifeSciences has moved within a fairly tight consolidating range over the past month, sitting near the $16–$17 area after sharper swings earlier in the year. With a market capitalization in the low-to-mid $200 million range and no revenue reported, valuation rests almost entirely on clinical milestones and the odds of eventual regulatory approval rather than current financials. Volume has stayed modest and often below average, typical for a clinical-stage biotech waiting on specific catalysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Greenwich LifeSciences Business and Competitive Position
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company based in Stafford, Texas. Its main candidate, GLSI-100, pairs the HER2-derived peptide GP2 with GM-CSF to create an immunotherapy aimed at lowering breast cancer recurrence risk after standard therapy. The program is in FLAMINGO-01, a global Phase III trial that carries Fast Track status from the FDA. Earlier Phase IIb results indicated an 80% or greater reduction in recurrence over five years in HER2/neu 3+ patients, which could set it apart in an area with clear unmet need. The firm is still pre-revenue and funds operations through equity raises, so cash runway and enrollment pace remain central to the story. From what I see, that positions the investment case around discrete trial updates.
Recent Developments and Analyst Views
A few items shaped trading in the past 30 days. Late October brought additional proxy materials filed with the SEC and the annual meeting set for December 18, 2026. Weiss Ratings downgraded the stock to Sell on October 29, 2026. On the other side, HC Wainwright kept its Buy rating and $69 target, well above the overall Hold consensus. The Q2 2026 loss came in at $0.27 per share versus the $0.33 estimate. Management continues to advance manufacturing and regulatory steps, including prior FDA and EMA clearances for commercial GP2 supply in the trial. I’m watching this closely as the binary nature of the setup keeps sentiment split.
2026 Outlook and Items to Monitor
The main focus for 2026 stays on FLAMINGO-01 progress—enrollment, immune data, and any fresh recurrence observations from the open-label portion. Additional regulatory clearances in the UK and Canada, plus manufacturing scale-up ahead of a potential BLA, form the longer-term backdrop. Near-term items include the Q3 2026 earnings release expected around November 13, 2026, with a projected $0.34 per share loss, cash position updates, patent news, and the insider lock-up that runs through January 31, 2027. As with any clinical-stage biotech, risks remain elevated around trial outcomes, regulatory decisions, and funding needs.
Exploring AI Tools for Market Patterns
In my own process I occasionally review Tickeron’s AI Trading Bots to see how systematic models handle event-driven names like this one. The platform surfaces top-performing strategies across many tickers, letting users compare approaches that fit different timeframes and risk levels without replacing core fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GLSI's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for GLSI turned positive on October 26, 2026. Looking at past instances where GLSI's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for GLSI crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +9.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 212 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 57 of 61 cases where GLSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLSI as a result. In 81 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
GLSI moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
GLSI broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (76.995) is slightly higher than the industry average of (3.051). P/E Ratio (-10.283) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement